Breaking Down YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors

Investors probing YiChang HEC ChangJiang Pharmaceutical Co., Ltd. will find a company marked by striking volatility and clear inflection points: revenue plunged to CNY 3.72 billion in 2024, a 40.84% decline after a 68.08% surge in 2023, while net income tumbled to CNY 482.71 million (down 75.78%), driving a sharp drop in profit margin to 12.96% and an operating margin of -11.76%; yet valuation metrics show divergent expectations with a trailing P/E of 24.27 versus a forward P/E of 5.56, a P/S of 3.53 and a P/B of 1.51, the market cap sitting around HK$13.97 billion (HK$12.81 billion as of July 1, 2025), total cash at HK$1.54 billion but levered free cash flow at -HK$102.19 million, a current ratio of 1.77 and debt-to-equity of 26.27, a book value per share of HK$9.67 and a special cash dividend of HK$1.5 per share slated for October 31, 2025-counterbalanced by a growth playbook that includes over 20 new drugs, self-developed insulin launches, approvals for Olorigliflozin and Encofosbuvir Tablets, plans to boost production capacity by 20% and a target to price some medicines ~10% below industry averages

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK) - Revenue Analysis

• Driver: One-time events, product cycle timing, or recognition shifts could explain the year-to-year swings; investors should review segment and product-level revenue timing.
• Valuation: P/S of 3.53 suggests a pricier revenue multiple - compare with peers to assess relative over/undervaluation.
• Productivity: CNY 766,050 revenue per employee signals moderate efficiency; productivity improvements or headcount changes will materially affect margins.

• New launches: self-developed insulin products are being rolled out to capture chronic disease markets.
• Approvals: Olorigliflozin and Encofosbuvir Tablets have regulatory approvals, potentially shifting future revenue mix toward innovative drugs.
• Strategic implication: expanding innovative drug portfolio can support higher-margin revenue if commercialization and market uptake proceed as planned.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK) - Profitability Metrics

• Net income (2024): CNY 482.71 million - down 75.78% from CNY 1.99 billion in 2023.
• Operating income (2024): CNY 674.47 million - down from CNY 2.35 billion in 2023.
• EBITDA (2024): CNY 1.05 billion - down from CNY 2.75 billion in 2023.
• Profit margin (2024): 12.96% vs 31.68% in 2023.
• Operating margin (2024): -11.76% (negative, indicating operational losses).
• Return on assets (ROA, 2024): 3.32%.
• Return on equity (ROE, 2024): 5.87%.

• Implication 1: The 75.78% fall in net income with a simultaneous negative operating margin (-11.76%) implies that core operations failed to cover operating costs in 2024.
• Implication 2: EBITDA decline to CNY 1.05 billion from CNY 2.75 billion reduces near-term cash-generation capacity and cushions for interest, tax, and capex needs.
• Implication 3: ROA of 3.32% and ROE of 5.87% are below typical pharma industry averages, pointing to suboptimal asset and equity utilization that may pressure investor returns.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK) Debt vs. Equity Structure

• Total debt: Not specified in available sources - limits full external assessment of absolute leverage.
• Debt-to-Equity Ratio: 26.27 - moderate leverage, indicating debt equals ~26.27% of shareholders' equity.
• Current Ratio: 1.77 - suggests adequate short-term liquidity to cover current liabilities.
• Book Value per Share: HK$9.67 - indicates net asset value attributable per share on the balance sheet.
• Special Cash Dividend: HK$1.50 per share - announced with payment scheduled for October 31, 2025.
• Key dividend dates: Ex-dividend date July 31, 2025; Record date August 4, 2025.

• Implication: With a debt-to-equity of 26.27 and current ratio of 1.77, the balance sheet shows relative resilience, though the absence of a specified total debt figure prevents full assessment of absolute leverage and maturity/profile risk.
• Shareholder returns: The HK$1.50 special dividend increases cash return to shareholders; observe ex-dividend/record dates for entitlement.
• Book value context: HK$9.67 per share provides a baseline for net asset valuation versus market price when assessing margin of safety.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK) - Liquidity and Solvency

• Total cash (most recent quarter): HK$1.54 billion - a strong cash buffer on the balance sheet.
• Operating cash flow (TTM): HK$97.92 million - positive cash generation from core operations.
• Levered free cash flow (TTM): -HK$102.19 million - negative after financing/debt service impacts.
• Current ratio: 1.77 - indicates sufficient short-term assets to cover short-term liabilities.
• Quick ratio: not specified in available sources - exclusion of inventory impact cannot be precisely determined.
• Solvency: detailed long-term debt breakdown not fully disclosed in the provided data, so long-term solvency remains partially unclear despite reasonable short-term coverage.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK) - Valuation Analysis

Key valuation metrics for YiChang HEC ChangJiang Pharmaceutical Co., Ltd. point to a stock that the market currently prices with moderate premiums relative to book value but with a materially lower forward earnings multiple, implying either expected earnings acceleration or depressed current earnings.

• Trailing P/E: 24.27 - indicates current historical earnings valuation.
• Forward P/E: 5.56 - implies the market expects significant earnings improvement (or one-time adjustments) ahead.
• Price-to-Book (P/B): 1.51 - stock trading at a modest premium to book value.
• EV/Revenue: 3.73 - offers context on how enterprise value compares to revenue generation.
• EV/EBITDA: 13.19 - suggests the company is valued at a mid-teens multiple of operating cash profits.
• Market Capitalization: HK$12.81 billion (as of July 1, 2025) - market-implied company size and investor confidence.
• 52-week range: HK$7.92 - HK$15.54 - demonstrates recent price volatility.
• Dividend yield: 1.57% with forward annual dividend HK$0.23 - modest income component for shareholders.

• Investor implications: the wide gap between trailing and forward P/E merits due diligence on earnings drivers (new product launches, one-off items, or forecasted margin expansion).
• Relative valuation: P/B ~1.5 and EV/EBITDA ~13 suggest the stock is neither deeply discounted nor richly priced versus typical pharma benchmarks - compare with direct peers for context.
• Income vs. growth trade-off: low dividend yield (1.57%) signals that total return expectations will likely rely more on capital appreciation tied to earnings growth.

For additional context on the company's strategic direction and values, see: Mission Statement, Vision, & Core Values (2026) of YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK) - Risk Factors

• Sharp revenue decline: Revenue fell by 40.84% in 2024, raising questions about the sustainability and predictability of top-line performance and market demand for core products.
• Profitability deterioration: Net income decreased by 75.78% in 2024, signaling significant pressure on margins and potential issues in cost controls or pricing power.
• Negative operating margin: The operating margin reached -11.76% in 2024, indicating the company is operating at an operational loss before interest and taxes.
• Negative levered free cash flow: Levered free cash flow was -HK$102.19 million, pointing to cash outflows after financing obligations and limiting internal funding for R&D, capex, or debt reduction.
• Moderate leverage: Debt-to-equity ratio stands at 26.27, reflecting moderate indebtedness that could become burdensome if earnings remain depressed or interest costs rise.
• Concentration risk: Heavy reliance on a small portfolio (notably insulin and hepatitis C treatments) exposes the company to competitive pressures, patent or pricing changes, and regulatory shifts that could disproportionately impact revenue.

• Revenue volatility: A single-year 40.84% drop may reflect product-specific issues (pricing pressure, tender losses, reimbursement changes) or one-off events; recurrence risk is material.
• Margin compression: The -11.76% operating margin combined with a 75.78% net income decline suggests fixed-cost absorption problems and potential write-downs or restructuring charges.
• Cash strain and funding risk: Negative levered FCF (-HK$102.19M) restricts flexibility to invest in new product development or acquisitions without external financing, increasing reliance on debt or equity raises.
• Leverage sensitivity: While a 26.27 debt-to-equity ratio is moderate, prolonged earnings weakness or higher interest rates could stress covenant compliance or increase refinancing costs.
• Product concentration and competitive/regulatory exposure: Dependence on insulin and hepatitis C drugs increases vulnerability to generic competition, pricing reforms, or regulatory restrictions in major markets.
• Execution risk in cost control: A steep net income decline underscores the need for tighter cost management and improved operational efficiency to return to positive operating margins.

• Downside scenario: Continued revenue declines (>20% YoY) plus flat gross margins would deepen operating losses and push levered FCF further negative, heightening refinancing risk.
• Stabilization scenario: Revenue stabilization with modest margin recovery could still leave limited free cash flow unless working capital turns and capex are curtailed.
• Upside scenario: Successful product diversification or market share recovery in insulin/hepatitis C could restore top-line growth and improve leverage metrics.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK) - Growth Opportunities

• Pipeline scale: over 20 new drugs in development, with at least 5 expected to reach the market by 2024.
• Recent approvals and launches: self-developed insulin products plus approved innovative drugs such as Olorigliflozin and Encofosbuvir Tablets - each creating new revenue streams in diabetes and antiviral segments.
• Therapeutic focus: expanding chronic disease portfolio (e.g., diabetes, cardiovascular, liver disease) and innovative drug classes to address growing long-term care needs.
• Capacity expansion: plan to increase production capacity by 20% by 2024 to support higher volumes and improve supply reliability.
• Pricing strategy: commitment to offering medications at prices ~10% below industry average by 2024 to enhance market penetration and competitiveness.
• External innovation: collaborations with international research institutions to accelerate drug discovery, clinical development and access to novel technologies.

• Revenue mix implications: launches in diabetes and antivirals should diversify revenue beyond legacy products and increase high-margin innovative drug contribution as approvals roll out.
• Operational leverage: 20% capacity uplift can reduce unit costs if utilization rises with new product demand; combined with 10% lower pricing, expected to drive volume-led growth.
• Risk-to-reward dynamics: timing of approvals, market uptake of new drugs and execution of capacity expansion are key near-term drivers for investor returns.